Impacting Commercial Lines of Business
Effective Aug. 1, 2025, Blue Cross Blue Shield of North Dakota (BCBSND) has updated the Long-Acting Insulin Prior Authorization (PA) Program to include additional agents: Toujeo, Basaglar and Insulin glargine 300 units/ml.
The complete list of program target agents is shown below.
Preferred Agent(s)
- Glargin-yfgn (insulin glargine-yfgn)
- Semglee (insulin glargine-yfgn)
- Toujeo (insulin glargine)
Non-Preferred Target Agent(s)
- Insulin glargine
- Lantus (insulin glargine)
- Rezvoglar (insulin glargine-aglr)
- Basaglar (insulin glargine)
- Insulin glargine 300 units/ml
To view this PA program summary, visit Long Acting Insulin Prior Authorization with Quantity Limit Program Summary.
Questions?
Contact our Provider Service Center at 800-368-2312.